Clinical trials: Cholesterol
Alzheimer Disease
The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease
The purpose of this study is to determine whether short-term use of the drugs ibuprofen and lovastatin affects levels of a protein called beta-amyloid in people who are at risk for developing Alzheimer's Disease (AD).
- Trial name
- NCT00046358
- Testing
- Lovostatin, Ibuprofen
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Cholesterol Ester Storage Disease(CESD), Lysosomal Acid Lipase Deficiency
An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype
This is a Natural History study to characterize key aspects of the clinical course of late onset Lysosomal Acid Lipase (LAL) Deficiency/ Cholesteryl Ester Storage Disease (CESD).
- Trial name
- NCT01528917
- Where
- 16 sites in United States, Canada and 6 more
- Volunteers
- 49 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Autism Spectrum Disorder, Autism
Exome Sequencing in Autistic Spectrum Disorder
Background: Research into the genetic causes of autism spectrum disorder (ASD) involves studies of the DNA of children with autism.
- Conditions
- Autism Spectrum Disorder, Autism, Autistic Disorder
- Trial name
- NCT01059201
- Where
- 3 sites in United States
- Volunteers
- 322 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Familial Hypercholesterolemia
Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
The main purpose of this study is to describe the safety and tolerability of 80 weeks of subcutaneous (SC) evolocumab when added to standard of care in children 10 to 17 years of age with familial hypercholesterolemia.
- Trial name
- HAUSER-OLE (NCT02624869)
- Testing
- Evolocumab
- Where
- 46 sites in United States, Australia and 21 more
- Volunteers
- 163 people
- Sponsor
- Amgen
Dyslipidemias, Lipid Disorder
Assessment of Different Equations to Accurately Calculate LDL Cholesterol
Purpose The LDL-C is a very important marker of the lipid panel which allows the introduction of a treatment and then the follow-up to prevent the cardiovascular risk.
- Trial name
- LDL FORMULA (NCT05598216)
- Testing
- no intervention, Serum LDL cholesterol calculation
- Where
- France
- Volunteers
- 160,000 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon